NCT01830998

Brief Summary

The rate of cognitive decline due to ageing is increased 1.5-fold to 2.0-fold in individuals with type 2 diabetes.There are no established specific treatment measures to prevent or ameliorate cognitive impairments in patients with diabetes. we want to detecte early clinical dementia in diabete.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
400

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2012

Typical duration for all trials

Geographic Reach
1 country

3 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2012

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

April 1, 2013

Completed
11 days until next milestone

First Posted

Study publicly available on registry

April 12, 2013

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2014

Completed
Last Updated

December 10, 2014

Status Verified

December 1, 2014

Enrollment Period

2.9 years

First QC Date

April 1, 2013

Last Update Submit

December 9, 2014

Conditions

DementiaDMMCI

Keywords

DementiaOlfactory

Outcome Measures

Primary Outcomes (1)

  • MMSE Olfactory function dementia

    MMSE,Olfactory function and PET(fMRI) were observed.

    2 years

Study Arms (4)

control,MCI, Olfactory dsfunction

There are different groups:control,MCI, Olfactory dsfunction.

control, MCI

control and MCI group.Glycaemic control

control and MCI

treatment and without treatment

MCI and Olfactory function

observation between MCI and Olfactory function groups.

Eligibility Criteria

Age50 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with type 2 diabetes

You may qualify if:

  • Patients with type 2 diabetes(Age\>50 years)

You may not qualify if:

  • with stroke or other complications.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Wuhan general hospital of Guangzhou Command

Wuhan, Hubei, 430070, China

RECRUITING

tongji Medical University

Wuhan, Hubei, 430074, China

ENROLLING BY INVITATION

Wuhan general hospital of Guangzhou command

Wuhan,chongqing, Hubei, 430070, China

ACTIVE NOT RECRUITING

Biospecimen

Retention: NONE RETAINED

serum

MeSH Terms

Conditions

DementiaAnosmia

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesNeurocognitive DisordersMental DisordersOlfaction DisordersSensation DisordersNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Central Study Contacts

xuzhipeng Wuqiang lihonghua, doctor

CONTACT

1387116839221823074@qq.com

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
doctor

Study Record Dates

First Submitted

April 1, 2013

First Posted

April 12, 2013

Study Start

January 1, 2012

Primary Completion

December 1, 2014

Study Completion

December 1, 2014

Last Updated

December 10, 2014

Record last verified: 2014-12

Locations

CN(3)